Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | APEX1 | P27695 | 1/20 | 0.97 |
| ▸ | BLM | P54132 | 1/20 | 0.97 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.97 |
| ▸ | PDE4A | P27815 | 1/20 | 0.59 |
| ▸ | AGO2 | Q9UKV8 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL8054947 | 0.99 | MAPT (1.00) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7835971 | 0.91 | HTR6 (0.83) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7835135 | 0.90 | HTR6 (1.00) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7834367 | 0.88 | HTR6 (0.78) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7826353 | 0.88 | HTR6 (0.78) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7833565 | 0.88 | HTR6 (0.78) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7837390 | 0.87 | HTR6 (0.78) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7836254 | 0.87 | HTR6 (0.76) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| SCHEMBL7834630 | 0.86 | HTR6 (0.76) | HTR6MAPTALDH1A1CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL8055897 | 0.86 | MAPT (0.78) | HTR6MAPTALDH1A1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN UNIVERSITY (US) | 2021-01-26 | — | — | US | claimed |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | CASE WESTERN RESERVE UNIVERSITY (US) | 2020-02-25 | — | — | US | claimed |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN UNIVERSITY | 2019-08-22 | — | — | US | claimed |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-04-30 | — | — | US | claimed |
| EP-3151818-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | Case Western Reserve University (US) | 2017-04-12 | — | — | EP | claimed |
| WO-2015187942-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | CASE WESTERN RESERVE UNIVERSITY (US) | 2015-12-10 | — | — | WO | claimed |
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY | 2014-08-21 | — | — | US | claimed |
| WO-2013063269-A2 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-05-02 | — | — | WO | claimed |
| EP-1799306-B1 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2011-02-23 | — | — | EP | claimed |
| EP-1971334-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | Wyeth a Corporation of the State of Delaware (US) | 2008-09-24 | — | — | EP | claimed |
| WO-2007087151-A2 | COMBINATION OF ACHE INHIBITOR AND 5-HT6 ANTAGONIST FOR THE TREATMENT OF COGNITIVE DYSFUNCTION | WYETH (US) | 2007-08-02 | — | — | WO | claimed |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | WYETH (US) | 2007-07-19 | — | — | US | claimed |
| EP-1799306-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. Hoffmann-Roche AG (CH) | 2007-06-27 | — | — | EP | claimed |
| WO-2006037482-A2 | COMPOSITIONS AND METHODS FOR TREATING COGNITIVE DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | ROCHE PALO ALTO LLC | 2006-03-30 | — | — | US | claimed |
| EP-0815861-B1 | Sulphonamides and their use | HOFFMANN LA ROCHE (CH) | 2001-09-19 | — | — | EP | claimed |
| EP-0815861-A1 | Sulphonamides and their use | F. HOFFMANN-LA ROCHE AG (CH) | 1998-01-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235562-A1 | COMPOUNDS AND METHODS OF TREATING OCULAR DISORDERS | ALDH1A2, TXNRD2, TXNRD1 | HTR6 1889/4885MAPT 689/4885ALDH1A1 607/4885 |
| US-20060069094-A1 | Compositions and methods for treating cognitive disorders | HTR6, HTR2A, HTR2C | HTR6 1/4885MAPT 381/4885ALDH1A1 3003/4885 |
| US-20190255102-A1 | COMPOSITIONS AND METHODS OF TREATING DIABETIC RETINOPATHY | GPR119, ARRB1, GRK1 | HTR6 783/4885MAPT 2830/4885ALDH1A1 647/4885 |
| US-10272106-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | HTR6 783/4885MAPT 2830/4885ALDH1A1 647/4885 |
| US-20070167431-A1 | Method for the treatment of cognitive dysfunction | ACHE, BCHE, HTR6 | HTR6 3/4885MAPT 285/4885ALDH1A1 1244/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | HTR6 376/4885MAPT 377/4885ALDH1A1 687/4885 |
| US-10568851-B2 | Compounds and methods of treating ocular disorders | ALDH1A2, TXNRD2, TXNRD1 | HTR6 1889/4885MAPT 689/4885ALDH1A1 607/4885 |
| US-10898516-B2 | Compositions and methods of treating diabetic retinopathy | GPR119, ARRB1, GRK1 | HTR6 783/4885MAPT 2830/4885ALDH1A1 647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.